About Event
The 3rd Kinase Targeted Drug Discovery Summit returns in 2025 to offer a transformative experience where innovation meets collaboration. As a free-to-attend event dedicated to drug developers and researchers in the kinase community, this is your chance to connect with leading experts in biology, chemistry, drug discovery, proteomics, and structural biology – all focused on advancing kinase therapeutics!
Building on the previous year’s success, this forum is tailored to offer cutting-edge advancements within kinase biology. Whether through maximizing mutant-selective inhibition or optimizing PK/PD safety profiles, join us at the future of kinase drug discovery.
Unmissable Key Sessions:
Reimagine the industry’s approach to structure-guided design by harnessing AI and machine learning to detect conformational changes and improve compound-kinase bioactivity prediction with Harmonic Discovery
Dissect the mode of action for non-ATP competitive, isoform-specific inhibition of PI3Kd by monitoring its pharmacological activity to achieve a selectivity-matched PK profile and optimize its therapeutic potential with iOnctura
Identify signs of clinical resistance by extrapolating free energy calculations of protein-residue-mutation from physics-based modeling to unlock kinome-wide selectivity of WEE1 as well as DLK inhibitors with Schrodinger
Implement ground-breaking solutions to mutant-selective TYK inhibition by targeting ERBB2 through the discovery of Bayer’s new small molecule inhibitor to combat non-small cell lung cancer (NSCLC) with Dana-Farber Cancer Institute
Who You Will Meet:
This unique forum is your golden ticket to join and network with 100+ kinase drug developers, researchers, and solution providers – all under one roof – with the shared interest of improving previous generations of kinase therapeutics. Get ready to hear from leading service providers showcasing game-changing technologies in kinase assays, phospho-proteomic profiling, AI drug design, and cryo-EM!
What Past Attendees Have Said:
"Focused meeting with some really high-quality science shared and discussed"
Senior Vice President, Black Diamond Therapeutics
"A valuable event because of the quality of the talks and the dialogue following the talks. Very unique opportunity"
President & Chief Executive Officer, Onconova Therapeutics
"This meeting was a time well spent, between various great and diverse presentations and networking with colleagues and CROs"
Vice President, TG Therapeutics